WEP Clinical
WEP Clinical is a privately held specialist CRO providing Phase I-IV clinical trial management, Expanded Access and Named Patient Programs, mobile clinical nursing, and global pharmaceutical distribution across 122 countries to biotech and pharmaceutical sponsors.
- Company typePrivate
- Founded2008
- HeadquartersMorrisville, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What WEP Clinical does
WEP Clinical is a privately held specialist Contract Research Organization (CRO) that delivers Phase I-IV clinical trial management, Expanded Access Programs (EAPs), Post-Trial Access Programs, Named Patient Programs, mobile clinical nursing, and global pharmaceutical distribution to biotech and pharmaceutical sponsors. Founded in 2008 as WE Pharma and rebranded to WEP Clinical in 2016 to reflect its 'With Every Patient' mission, the company positions itself as built for biotech sponsors with limited resources, distinguishing itself from large CROs through bespoke, flexible service configurations and end-to-end program management. Operations span 122 countries supported by four offices (London UK headquarters, Morrisville NC US headquarters, Dublin Ireland, and Breda Netherlands following the January 2026 acquisition of Siron Clinical).
The product portfolio is organized into three integrated divisions: WEP CRO Services covering trial planning and preparation, study startup, patient recruitment and retention, clinical support, biometrics, and study closeout; WEP Access Programs covering EAPs, Post-Trial Access Programs, Post-Approval Named Patient Programs (PA-NPPs), and third-party logistics; and Clinical Trial Nursing covering the WEP Flying Nurse Model and global operating model for decentralized home-based trial participation. Underlying technology includes IRT systems integration for randomization and drug supply management, patient feasibility and site selection analytics leveraging real-world data and epidemiological databases, and a licensed distribution infrastructure spanning Wholesale Distribution Authorizations, DEA and UK Home Office controlled substance licenses, and a UK Manufacturers 'Specials' License for secondary packaging.
Revenue is generated through bespoke, project-based service contracts with biotech and pharma sponsors, structured as multi-year engagements ranging from single-service needs to full end-to-end program management. Distribution of services is direct enterprise sales, while physical pharmaceutical distribution runs through approved specialist couriers for time- and temperature-sensitive shipments. The Jordan Company made an undisclosed private equity investment in November 2021 to support growth strategy. Leadership transitioned in November 2024 with co-founder Jaswinder Khera assuming sole company-wide CEO responsibilities after Jaswant Khera stepped away from day-to-day operations. The company has executed two strategic acquisitions: Wren Healthcare in 2020 (clinical nursing) and Siron Clinical in January 2026 (European CRO delivery), and announced a new London office at Chiswick Business Park in July 2026.
WEP Clinical firmographics
Firmographics- Name
- WEP Clinical
- Legal name
- WEP Clinical
- Website
- https://wepclinical.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- WEP Clinical is a privately held specialist CRO providing Phase I-IV clinical trial management, Expanded Access and Named Patient Programs, mobile clinical nursing, and global pharmaceutical distribution across 122 countries to biotech and pharmaceutical sponsors.
- Ownership category
- akta.pro rank
WEP Clinical industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)
Keywords
Where WEP Clinical is headquartered
LocationHeadquarters
- HQ city
- Morrisville
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
WEP Clinical business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- CRO Clinical Trial Services: Full-service CRO offerings including Phase I–IV trial planning, execution, monitoring, data management, biometrics, regulatory affairs, and study closeout. Revenue generated through project-based service contracts with biotech and pharmaceutical sponsors, structured as bespoke solutions tailored to each client's exact requirements.
- Expanded Access Programs (EAPs) & Post-Trial Access: Design and delivery of Expanded Access Programs and Post-Approval Named Patient Programs (PA-NPPs). WEP manages the end-to-end regulatory, logistics, and distribution process to supply unlicensed medicines to patients globally, returning positive ROI to sponsors.
- Mobile Clinical Nursing Solutions: Clinical home nursing services enabling patients to participate in trials from their homes. Includes country coordinator teams and in-house nursing staff acquired through Wren Healthcare acquisition in 2020.
- Global Drug Distribution & Supply Chain: Global distribution of pharmaceutical products through licensed wholesale and manufacturing channels, managing time- and temperature-sensitive shipments via approved specialist couriers. Covers 122 countries with in-house language capabilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Flexible bespoke service model — single-service or full-service program management |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels9 records
WEP Clinical product offering
Product offeringCore offering
WEP Clinical operates as a specialist Contract Research Organization (CRO) providing full-service Phase I–IV clinical trial management, Expanded Access Programs (EAPs), Post-Trial Access Programs, Post-Approval Named Patient Programs (PA-NPPs), mobile clinical nursing solutions for decentralized trials, and global pharmaceutical product distribution. The company supports 60+ clinical programmes and delivers investigational and licensed medicines across 122 countries, operating under WDA, Home Office/DEA, and UK Manufacturers 'Specials' licenses. Services span planning, regulatory affairs, biometrics, study closeout, and patient concierge support.
Product overview
WEP Clinical operates as a Complete CRO providing Drug Development, Treatment Access, and Commercialization Solutions through three integrated divisions: WEP CRO Services (Phase I-IV clinical trial management), WEP Access Programs (Expanded Access Programs, Post-Trial Access, Named Patient Programs), and Clinical Trial Nursing (mobile nursing solutions). The company supports 60+ clinical programs and delivers treatments across 122 countries, offering comprehensive services from planning through study closeout, including regulatory affairs, biometrics, pharmacovigilance, and specialized home nursing for decentralized trials.
Differentiator
Problem solved
Functional benefit
Products and services
- WEP CRO Services Full-service Phase I–IV clinical trial management for biotech and pharma sponsors, including planning, trial initiation, patient recruitment, execution monitoring, data management, biometrics, and study closeout.
- WEP Access Programs End-to-end Expanded Access Programs (EAPs) and Post-Trial Access solutions including Post-Approval Named Patient Programs (PA-NPP), Market Access Solutions, and 3PL services, supplying unlicensed or locally unavailable medicines to patients globally.
- Clinical Trial Nursing
Quantifiable outcome
- 210+ clinical programs delivered, 12,500+ patients served, 500+ sites managed
- +2 more outcomes
Companies that use WEP Clinical
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
WEP Clinical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
WEP Clinical partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered minor, core and major.
- Oliver Patch ProjectminorWEP Clinical joined the Oliver Patch Project to champion children facing serious illness through National Patch Day. This is a patient advocacy/community engagement partnership supporting pediatric patients and their families.
- Siron ClinicalcoreWEP Clinical acquired Netherlands-based CRO Siron Clinical in January 2026. The acquisition expands WEP's global Phase I–IV trial delivery capabilities, adding European operational infrastructure in the Netherlands. This represents a significant strategic expansion of WEP's CRO service offerings.
- PlusUltra PharmamajorPartnership with PlusUltra Pharma to supply HYFTOR® (sirolimus) gel to patients in EU/EEA countries (with the exception of Germany) through a named patient distribution program.
- Geron CorporationmajorPartnership with Geron Corporation for an Expanded Access Protocol for imetelstat, a novel telomerase inhibitor. WEP manages the EAP to provide access to the investigational drug for patients outside of the clinical trial setting.
- TheratechnologiesmajorPartnership with Theratechnologies to launch a Named Patient Program for EGRIFTA SV® (tesamorelin), providing access to the treatment for patients in specified regions.
- Pharming GroupmajorPartnership with Pharming Group to supply leniolisib post-FDA approval through a Post-Approval Named Patient Program. Previously partnered on an EAP for leniolisib in 2022.
- Solasia Pharma K.K.minorPartnership with Solasia Pharma K.K. to launch DARVIAS Named Patient Program for access to this oncology product.
- Y-mAbs TherapeuticsmajorPartnership to provide DANYELZA® (naxitamab) through a Named Patient Access Program in Europe for pediatric neuroblastoma patients.
- Taimed BiologicsmajorPartnership with Taimed Biologics to launch a TROGARZO® (ibalizumab-uiyk) Named Patient Program, providing access to this HIV treatment for patients in ex-US countries.
- Kiniksa PharmaceuticalsmajorPartnership with Kiniksa to launch ARCALYST® (rilonacept) Named Patient Program, providing access for patients with autoinflammatory conditions.
- Sellas Life Sciences GroupminorPartnership with Sellas Life Sciences Group to launch an Expanded Access Program for galinpepimut-S, a WT1-targeted immunotherapeutic.
- MedlabminorMaster Services Agreement with Medlab to bring NANABIS™ and NANOCBD™ to patients in the UK and Europe via ethical named patient programmes.
- Nabriva TherapeuticsmajorPartnership with Nabriva Therapeutics expanded the availability of XENLETA® (lefamulin) Named Patient Program globally.
- BTG Specialty PharmaceuticalsmajorPartnership with BTG Specialty Pharmaceuticals for European supply of VORAXAZE® (prothrombin complex concentrate). Extended in 2021 to gain worldwide (ex-US) distribution rights for DIGIFAB® (digoxin immune fab).
- Wren HealthcarecoreAcquisition of Wren Healthcare (specialist nursing and clinical education company founded by Antony Reynolds in 2018) in 2020. This acquisition brought in-house clinical nursing capabilities to WEP, forming the foundation of WEP's mobile nursing solutions.
- Mylan (now Viatris)majorPartnership with Mylan to provide product for highly drug-resistant tuberculosis, supporting global access to critical anti-infective treatments.
- Wellstat Therapeutics CorporationmajorPartnership for Named Patient supply of VISTOGARD® (uridine triacetate) for the treatment of patients experiencing toxicity from fluorouracil or capecitabine overdose.
Scale indicators7 records
Recent moves11 records
Expansion highlights6 records
WEP Clinical competitors and assessment
Company assessmentDirect peers
- Clinigen Group: UK-headquartered specialty pharma services company with overlapping Expanded Access Program, Named Patient Program, and clinical trial supply capabilities — the closest direct competitor in the global access-program and unlicensed-medicines distribution space.
- Inceptua Group: Specialty pharma services provider focused on compassionate use, expanded access, and clinical trial supply across multiple geographies — direct overlap with WEP's access programs and global drug distribution offerings.
- Worldwide Clinical Trials: Mid-sized global CRO with deep Phase I-IV trial expertise; WEP's CFO Karl Challender previously held senior roles there, evidencing comparable operating model and therapeutic coverage, especially in biotech-focused studies.
- Veristat: Specialty CRO focused on complex clinical trials for small and mid-sized biopharma; comparable to WEP in biotech-centric positioning, agile bespoke service model, and senior leadership pedigree (WEP COO Shaheen Limbada previously worked at Veristat).
- Medpace Holdings: Public CRO explicitly built around serving small and mid-sized biotech sponsors with full-service Phase I-IV trial delivery — the most direct publicly traded comp for WEP's 'built for biotech' positioning and operating model.
Broad incumbents
- IQVIA: Largest global CRO and clinical research services provider; overlaps broadly with WEP's Phase I-IV, biometrics, and patient recruitment offerings but at materially larger scale and with broader pharma focus.
- ICON plc: Global CRO formed through PRA Health Sciences merger, providing full-service clinical development across all phases; competes for the same biotech sponsor wallet with broader therapeutic and geographic coverage than WEP.
- Thermo Fisher Scientific (PPD): Owns PPD, a top global CRO; WEP's EVP Commercial Lee Sutton spent 7 years in Thermo Fisher global commercial leadership, evidencing deep familiarity with PPD's go-to-market as a competitor across CRO and access services.
- Syneos Health: Large CRO with biotech and biopharma focus spanning clinical development and commercialization; overlapping client base and service scope with WEP but at significantly greater scale.
- Labcorp (Covance Clinical Development): Diversified diagnostics and drug development company whose Covance segment offers global CRO services spanning Phase I-IV — broad incumbent competing with WEP for biotech clinical trial and central lab business.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
WEP Clinical social profiles
Digital presenceWEP Clinical financial estimates
Financial estimateRevenue estimate
Valuation estimate
WEP Clinical leadership team
Management profileNumber of profiles
Profiles12 records
WEP Clinical subsidiaries and ownership
Company hierarchySubsidiaries2 records
WEP Clinical funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WEP Clinical M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WEP Clinical
What does WEP Clinical do?
WEP Clinical operates as a specialist Contract Research Organization (CRO) providing full-service Phase I–IV clinical trial management, Expanded Access Programs (EAPs), Post-Trial Access Programs, Post-Approval Named Patient Programs (PA-NPPs), mobile clinical nursing solutions for decentralized trials, and global pharmaceutical product distribution. The company supports 60+ clinical programmes and delivers investigational and licensed medicines across 122 countries, operating under WDA, Home Office/DEA, and UK Manufacturers 'Specials' licenses. Services span planning, regulatory affairs, biometrics, study closeout, and patient concierge support.
Is WEP Clinical a public or private company?
WEP Clinical is a private company. It is classified as private equity controlled and is currently operating.
When was WEP Clinical founded?
WEP Clinical was founded in 2008. It employs 101 to 250 people.
Where is WEP Clinical based?
WEP Clinical is headquartered in Morrisville, United States, in the North America region.
How does WEP Clinical make money?
Four revenue lines are on record. CRO Clinical Trial Services are the primary driver. The others are expanded Access Programs (EAPs) & Post-Trial Access, mobile Clinical Nursing Solutions and global Drug Distribution & Supply Chain.
Who are WEP Clinical's main competitors?
Direct peers on record are Clinigen Group, Inceptua Group, Worldwide Clinical Trials, Veristat and Medpace Holdings. Broad incumbents are IQVIA, ICON plc, Thermo Fisher Scientific (PPD), Syneos Health and Labcorp (Covance Clinical Development).
Does WEP Clinical have an API?
No public API is recorded for WEP Clinical.
What industry is WEP Clinical in?
WEP Clinical's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs. Its NAICS code is 5417 and its SIC code is 8731.